One Day Advisor

Which industries could lose as Ozempic, Wegovy, Mounjaro, and Zepbound change appetite, food spending, and obesity care? Compare six sectors, their GLP-1 exposure scores, illustrative stock baskets, and the evidence behind the investment thesis. OneDayAdvisor research framework · Updated October 24, 2026 GLP-1 medicines are no longer just a pharmaceutical-industry story. By changing appetite, body weight, and metabolic health, these medicines could influence industries ranging from packaged snacks and alcoholic beverages to bariatric surgery, sleep-apnea treatment, orthopedic procedures, and kidney care. For investors, the important question is not simply which businesses are associated with obesity. It is which companies could experience measurable changes in product volumes, procedure demand, or long-term healthcare utilization as GLP-1 medicines become more widely used. The clearest current consumer-sector signal is in some packaged-food categories. Bariatric s...

Updated October 21, 2026 · Originally published July 2025 · Written by the One Day Advisor Editorial Team · Reviewed by Frank Yap, MBA. Prices and fund data are as of October 16–21, 2026 unless another date is shown. Figures marked “est.” are unconfirmed and should be checked on the issuer’s fund page. Quick Answer As of October 21, 2026, the lowest-cost gold ETFs are IAUM (0.09%) and GLDM (0.10%), IAU (0.25%) offers scale, and GLD (0.40%) is the most liquid. For silver, SLV (0.50%) is the liquid benchmark and SIVR (0.30%) is the cheaper hold. Gold is near $4,127 an ounce, about 23% below its January record, so miner and leveraged funds carry far more risk than bullion funds. Disclosure This article is educational and is not financial or investment advice. Some links to TradingView are affiliate links; we may earn a commission at no cost to ...